SEOM clinical guidelines in Hereditary Breast and ovarian cancer
Authors:
- On behalf of the SEOM Hereditary Cancer Working GroupOGOn behalf of the SEOM Hereditary Cancer Working Group
- G. LlortGLG. Llort
- A. TeuléATA. Teulé
- J. BrunetJBJ. Brunet
- J. BalmañaJBJ. Balmaña
Open Access
- 15 December 2015
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 17 (12) , 956-961
Abstract
Approximately, 7 % of all breast cancers (BC) and 11–15 % of ovarian cancers (OC) are associated with inherited predisposition, mainly related to germline mutations in high penetrance BRCA1/2 genes. Clinical criteria for genetic testing are based on personal and family history to estimate a minimum 10 % detection rate. Selection criteria are evolving according to new advances in this field and the clinical utility of genetic testing. Multiplex panel testing carries its own challenges and we recommend inclusion of genes with clinical utility. We recommend screening with annual mammography from age 30 and breast MRI from age 25 for BRCA1 and BRCA2 mutation carriers. Bilateral salpingo-oophorectomy should be offered to women with a BRCA1 or BRCA2 mutation, between 35 and 40 years and after completion of childbearing, or individualise based on the earliest age of ovarian cancer diagnosed in the family. Bilateral risk-reducing mastectomy is an option for healthy BRCA1 and BRCA2 mutation carriers, as well as contralateral mastectomy for young patients with a prior BC diagnosis. BRCA genetic testing in patients with BC and OC may influence their locoregional and systemic treatment.Keywords
This publication has 31 references indexed in Scilit:
- Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJournal of Clinical Oncology, 2013
- Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACEJNCI: Journal of the National Cancer Institute, 2013
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian CancerJournal of Clinical Oncology, 2012
- Quality and Strength of Evidence of the Infectious Diseases Society of America Clinical Practice GuidelinesClinical Infectious Diseases, 2010
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation CarriersJNCI: Journal of the National Cancer Institute, 2009
- Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutationBritish Journal of Cancer, 2008
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2005